-

Life Sciences Entrepreneur John Flavin launches Portal Innovations

Partners with Trammell Crow Company to provide start-up lab space

CHICAGO--(BUSINESS WIRE)--Portal Innovations, LLC today announced they are launching a new platform to seed and accelerate life sciences, medtech and bioinformatics ventures. The company is the brainchild of John Flavin, a seasoned life sciences executive and entrepreneur with over 25 years of industry experience in finance, operations and innovation. In addition to providing management expertise, team assembly and other start-up resources, Portal is partnering with Trammell Crow Company, a leading real estate developer in the United States, to design and develop wet and dry lab space to support a carefully curated portfolio of early stage companies in the recently announced Fulton Labs complex in Fulton Market.

“There is an increasing pipeline of talent and biomedical innovation emerging from Midwest universities and companies that have the potential to be novel products in the healthcare market. However, entrepreneurs need an ecosystem of strong business and science teams coupled with capital and lab space to move the innovation from proof of concept to commercialization,” said Raju Prasad Ph.D., Senior Biotechnology Equity Research Analyst at William Blair. “Portal is well positioned to successfully address this opportunity.”

Aware of this emerging opportunity in the Midwest, John Flavin created Portal Innovations to seed, build and scale early stage ventures emerging from academic laboratories, companies and innovation hubs.

“The nexus of talent, world-class universities, innovative companies and business incubators here in Illinois make up an entire ecosystem of opportunities that rivals any state in the nation,” said Governor JB Pritzker. “My administration’s five-year blueprint for Illinois’ economy identified life sciences as a key sector that would drive our state’s growth, and I’m excited to see Portal Innovations set up shop in Illinois and build a groundbreaking venture that will keep our state at the forefront of innovation.”

“John’s endeavor is so timely given that Illinois Universities have garnered more than $1 Billion in NIH funding annually for biomedical innovation setting the stage to commercialize more of this breakthrough science,” said Brad Henderson, CEO of P33 Chicago, a private sector led initiative driving global technology leadership for Chicago. “As a region, we’re developing a robust ecosystem with a strong bench of assets and innovators in the life sciences sector – a critical first step in our ability to translate these assets into industry-led commercial viability. ”

To Portal, John brings a strong track record of successful life sciences and medtech senior management experience and innovation expertise in both the start-up and established company setting. Most recently John served as Chief Financial Officer at Endotronix and helped them secure $70 million to fund their pivotal clinical program. In parallel, he cofounded Pyxis Oncology as founding chairman and helped the team raise a $22 million Series A round to launch its novel immuno-oncology antibody drug platform. Over his career, he has co-founded and scaled several life sciences companies as President and CFO including Advanced Life Sciences and MediChem Life Sciences and has also co-founded and led transformative life sciences incubators including MATTER and the Polsky Center for Entrepreneurship and Innovation at the University of Chicago. John has successfully raised over $345 million of public, private and philanthropic capital including 2 NASDAQ IPOs to fund the development of these impactful organizations.

“John is a prolific company builder. We’re grateful for his contributions over the last 2 years at Endotronix, which include securing our Series D financing and building a strong finance, legal, and accounting leadership team. His efforts have positioned us well to execute our clinical program and move to the next phase,” said Harry Rowland, co-founder and CEO of Endotronix.

About Portal Innovations, LLC

Portal Innovations is building a life sciences, medtech and bioinformatics start-up platform based in Chicago, Illinois. It is bringing together high-performing entrepreneurial teams, global capital and industry partners to accelerate biomedical innovations from discovery through commercial proof of concept. Portal is partnering with Trammell Crow Company to provide state-of-the art shared wet and dry labs for life sciences, medtech and bioinformatics companies. Learn more at www.portalinno.com.

Contacts

John Flavin
Founder & CEO, Portal Innovations, LLC
Phone: 630.297.1600
Email: john.flavin@portalinno.com

Portal Innovations, LLC


Release Versions

Contacts

John Flavin
Founder & CEO, Portal Innovations, LLC
Phone: 630.297.1600
Email: john.flavin@portalinno.com

More News From Portal Innovations, LLC

NJ Innovation Hub selects Portal Innovations as Partner to Manage Life Sciences Incubator at HELIX NJ

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Portal Innovations, a leading life sciences venture development engine, announced today a partnership with The NJ Innovation Hub, a cornerstone of The Health & Life Science Exchange of New Jersey (HELIX NJ), to design and manage 30,000 SF of innovation and lab incubation space in New Brunswick. Portal will help support life sciences startups and entrepreneurs from nearby research universities including Rutgers, Princeton, and NJIT, by providing them wit...

Portal Innovations Expands Internationally in Partnership with Dublin City University to Support Science Startups Across Ireland, UK, and Europe

DUBLIN & CHICAGO--(BUSINESS WIRE)--Portal Innovations, a leading life science venture development engine, today announced its international expansion through a strategic partnership with Dublin City University (DCU). This collaboration was established under a Memorandum of Understanding which expands Portal’s footprint at DCU Alpha – Dublin City University’s Innovation Campus – where Portal opened space earlier this year. Portal’s expansion at DCU Alpha will help create new opportunities for bi...

ClostraBio Gains INVENT Illinois Investment, Appoints New CSO, Announces Plans for First Product Launch in Summer 2025

CHICAGO--(BUSINESS WIRE)--ClostraBio, Inc., a biotechnology company focused on harnessing natural pathways to manage gut health, recently announced new institutional investors in their latest bridge financing round that includes capital from the Illinois Innovation Venture Fund (INVENT) and NextGen Nutrition Investment Partners (NGN). The INVENT program, administered by the Office of Entrepreneurship, Innovation & Technology at Illinois Department of Commerce and Economic Opportunity (DCEO)...
Back to Newsroom